May 14, 2020 | Adaptiiv, News
Read original here
Eckert Ziegler BEBIG (EZB) and Adaptiiv Medical Technologies Inc. (Adaptiiv) are pleased to announce an extension of their strategic partnership. EZB will resell Adaptiiv’s 3D printing software solution in select markets that include Germany, Austria, Switzerland, Italy, Spain, and France. The two companies previously completed compatibility testing between their respective platforms. Adaptiiv has released new features in version 3.0 of its software solution to ensure mutual customers can use the regulated solution.
EZB is a European-based group active in the production and distribution of medical products for the treatment of cancer using brachytherapy. Brachytherapy applies radioactive sources directly to or into the tumor, allowing a high dose to the tumor while sparing the surrounding healthy tissue. For the patient, this means shorter treatment periods, fewer side effects, and a faster recovery.
May 2, 2019 | Adaptiiv, News
Read the full Entrevestor article here
Adaptiiv Medical Technologies Inc., the Halifax company that uses 3D printing to improve cancer treatment, has further extended its international reach by partnering with Italian peer Eckert & Ziegler BEBIG, or EZB.
EZB specializes in products used in brachytherapy, which applies radioactive sources directly to or into tumors while sparing the surrounding healthy tissue. For the patient, this means shorter treatment periods, fewer side effects and a faster recovery.
The two companies announced Sunday they will test and align their systems to provide an integrated workflow for cancer centers to create 3D-printed brachytherapy applicators customized to each patient. They believe the collaboration will demonstrate that 3D printing can provide clinically viable solutions that improve treatment and patient care.
“This is a significant milestone for us,” said Adaptiiv CTO Alex Dunphy in the press release.“Collaborating with the team at EZB has allowed us to continue to make significant strides towards improving the standard of care using a patient-specific approach in brachytherapy. The successful alignment of our systems will demonstrate that 3D printing can be used to provide a clinically viable solution in brachytherapy treatment.”
Oct 26, 2018 | Adaptiiv, News
Read the original article here.
Halifax-based Adaptiiv has announced major new clients in Hong Kong and the U.S. as the young medical technology company expands its customer base to seven countries.
The company – which uses 3D printing technology to improve radiation therapy in cancer treatment – said Monday it had signed a deal to sell its product to University of Hong Kong and work with the institution as a research partner.
That announcement came days after Adaptiiv announced its 3D Bolus technology would be used by the U.S. Military at the Walter Reed National Military Medical Center. Dubbed “The Nation’s Medical Center,” the Reed is the United States’ largest and most renowned joint military medical facility, providing services in over 100 clinics and specialties.
“We have accomplished a lot in a short period of time and I am very proud of the team but I feel we are just getting started,” said CEO Peter Hickey in an email Sunday night.
Just two years old, Adaptiiv has quickly found customers for its 3D Bolus product, which revolutionizes the use of a bolus in radiation therapy. A bolus is a piece of plastic placed over the cancerous area, assuming the tumours are close to or in the skin. The radiation hits the bolus, builds up and then is transferred into the tumour.
There can be no air pockets between the bolus and the skin, which complicates matters given that every body is unique. Hospitals using the Adaptiiv product buy a system that includes 3D printers with special filaments, so boluses customized to each patient can be printed within seconds. They can be reused as the patient receives repeated radiation dosages. Or, if the patient’s body shape changes over the course of multiple treatments, the medical staff can print off another bolus quickly.
In June, the company announced it had received 510(k) clearance from the U.S. Food and Drug Administration, allowing the product to be sold in the U.S.
That opened the flood gates to more sales, and to announcements of new partnerships and projects. The company’s software is now used in the U.S., Canada, Australia, Israel, Ireland, England and now Hong Kong.
The university in Hong Kong will use 3D Bolus in radiation therapy and its Department of Clinical Oncology will work with Adaptiiv to develop new applications.
Meanwhile, Adaptiiv last week also released a new product called AccuCALC, which helps cancer centers to assess the business case for offering the 3D Bolus product. AccuCALC was developed by Churchill Consulting, which provides consulting and integrated system solutions to radiation therapy departments.
Rules for billing insurers vary from state to state in the U.S., and facilities that offer radiation therapy can use AccuCALC to assess how and when they can charge for using the 3D Bolus product.
“We have seen significant demand from our clients for information pertaining to 3D Bolus,” said Jordan Johnson, Churchill’s Director of Compliance. “Yet. as is common with many leading-edge technologies, our clients are unsure of whether they can bill for a new technology or its potential return on investment. AccuCALC addresses that problem.”]]>
Apr 18, 2018 | Adaptiiv, News
See original story here
The executive team of Halifax-based Adaptiiv, fresh with a recent round of financing, is attending an international radiotherapy conference in Barcelona this week to announce a new distribution partnership.
Formerly known as 3DBolus, Adaptiiv is a company that has been gaining notice in Halifax biotech circles for a couple of years, even though it just released its first public statement this week. The company has developed software that works with 3D printers to produce a personalized bolus — a plastic fitting used in radiation therapy.
Adaptiiv has launched three different products, booked sales in six countries and raised almost $3 million in equity funding. Last week Adaptiiv announced it had signed a distribution agreement with Iowa-based CIVCO Radiotherapy, which will give it sales representatives in all main districts of North America.
“This is a special company,” CEO Peter Hickey said in an interview Tuesday before jetting off to the Estro Conference in Spain. “When I was first approached by the team I initially thought, ‘This isn’t for me,’ because I was in IT. But the team, especially (board member) Bruce Ross, kept driving home the point that this is a software play. It was one of those cases where I fell in love with the company.”
Hickey is best known in the community as a serial entrepreneur in the IT space, most recently for being the CEO of Oris4, which shut down two years ago. In Adaptiiv, he’s teamed up with James Robar, chief of medical physics at the Nova Scotia Health Authority and director of medical physics graduate programs at Dalhousie University, and serial tech entrepreneur Alex Dunphy.
What Adaptiiv does is revolutionize the use of a bolus in radiation therapy. A bolus is a piece of plastic placed over the cancerous area, assuming the tumours are close to or in the skin. The radiation hits the bolus, builds up and then is transferred into the tumour.
There can be no air pockets between the bolus and the skin, which complicates matters given that every body is unique. Hospitals using the Adaptiiv product buy a system that includes 3D printers with special filaments, so unique boluses customized to each patient can be printed within seconds. They can be reused as the patient receives repeated radiation dosages. Or if the patient’s body shape changes over the course of multiple treatments, the medical staff can print off another bolus quickly.
The company has received its CE Mark certification, meaning it can sell into several countries including members of the European Union. It already has clients in the U.K., Ireland, Israel, Australia and Canada. It has applied for its 510k approval in the U.S. and Hickey said it hopes to receive approval “soon.”
Adaptiiv recently closed a round of funding which included investment from Alexander Capital in New York, an investment boutique that makes direct investments and rounds up angel investors to back companies. Hickey said Adaptiiv has now raised almost $3 million and is planning a larger raise once it receives its 510k approval.
Adaptiiv has three products in the market, including one that helps to prevent healthy organs from being damaged during radiation therapy. With nine employees (soon to be 12), the company continues to develop new products.
“We have a pipeline with some really great innovation,” said Hickey. “That’s what we are. We’re a Nova Scotian-based innovation company that’s producing solutions to problems that people haven’t solved yet.”]]>
Jul 5, 2017 | Encyt Technologies, News
See original story here
Encyt Technologies, Inc., a leading biotech cancer research organization based in Nova Scotia, Canada, recently filed a series of patents for novel treatments to reverse resistance to immunotherapy using checkpoint inhibitors.
According to Dr. William Harless, MD/PhD, and Encyt CEO: “ENCYT has been studying the expression pattern of a number of distinct cytokines following cancer treatments such as surgery and chemotherapy. Based on these patterns, we have been experimenting with therapeutic strategies to block this response as a rational treatment approach to cancer. Working with our collaborating scientists at Queen’s University, we are excited to report that our proprietary therapeutic approach has proven to be very successful at mitigating the development of drug resistance and metastasis in a very difficult to treat human pancreatic cancer cell line implanted into a heterotopic mouse xenograft model.” Dr. Harless went on to explain, “We think our current therapeutic approach may also prove effective as an adjuvant therapy with immunotherapy. This treatment can reverse a mesenchymal phenotype that is often predictive of resistance to these checkpoint blockers. Furthermore, three of the key oncogenic signaling pathways up-regulated in cancer patients who are resistant to checkpoint inhibitors are targeted using our therapeutic approach.”
Immunotherapy treatments with checkpoint blockers have proven to be game changing cancer treatments in a number of different cancers. But only a minority of patients will respond to these treatments, and most patients who initially respond to these treatments eventually become resistant. ENCYT has filed an additional two patents to protect their novel therapeutic strategy as an adjuvant treatment approach that might allow more patients to benefit from these often highly effective cancer treatments.
Encyt is currently seeking regulatory approval from Health Canada to conduct a clinical trial testing our therapeutic approach for the treatment of advanced Pancreatic Cancer. Please follow the company’s continued progress at www.encyt.net
About Encyt Technologies, Inc.
Encyt Technologies, Inc. is an early stage cancer research organization focused on developing novel therapies for the treatment of cancer. The company has developed novel approaches to blocking post-treatment metastatic cancer stem cell proliferation, drug resistant phenotype development and adjunct Immunotherapy enhancement therapies. The company was founded in 2014 and is based in Nova Scotia, Canada. Encyt is funded by a small group of private investors and has received additional funding support from the Atlantic Canada Opportunities Agency (“ACOA”), the National Research Council of Canada (“NRC”), and other private philanthropic organizations.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Encyt Technologies, Inc. to be materially different from the statements made herein.]]>
